Postsynaptic alpha-adrenoceptors in the perfused canine saphenous vein in vitro. 1991

J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
Department of Pharmacology, Faculty of Medicine, Portugal.

To study the relative localization of alpha 1 and alpha 2-adrenoceptors in relation to the intima and the adventitia of canine saphenous vein, a comparison was made of the potency of alpha 1- and alpha 2-adrenoceptor agonists applied by intraluminal and extraluminal route of perfused segments of that vessel. Noradrenaline was the most potent of the agonists used and was approximately as potent by intraluminal as by extraluminal route. Cocaine (12 mumol/l) caused supersensitivity to noradrenaline which was of about the same magnitude (threefold) irrespective of the route of administration of noradrenaline. The selective alpha 1-agonist phenylephrine was about 10 times less potent than noradrenaline and was also equieffective by both routes. The selective alpha 2-agonist UK-14,304, at concentrations lower than 0.3 mumol/l, caused very small responses and only in 3 out of 14 experiments. In all cases it caused responses at concentrations higher than 0.3 mumol/l. Cocaine did not change the sensitivity to either phenylephrine or UK-14,304. Thus, it is concluded that the results obtained with cocaine agreed with expectations for a homogeneously innervated tissue. Furthermore, alpha 1-adrenoceptors seem to predominate and to be evenly distributed throughout the media. The lack of responses to the low concentrations of UK-14,304--those selectively acting on alpha 2-adrenoceptors--was ascribed to the very low efficacy of this agonist on the distal part of the canine saphenous vein and to the tone created by the perfusion pressure which might be high enough to mask this small response.

UI MeSH Term Description Entries
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012501 Saphenous Vein The vein which drains the foot and leg. Saphenous Veins,Vein, Saphenous,Veins, Saphenous
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
October 1980, Anesthesiology,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
June 1984, The Journal of pharmacology and experimental therapeutics,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
November 1980, Naunyn-Schmiedeberg's archives of pharmacology,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
July 1985, The Journal of pharmacology and experimental therapeutics,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
January 1996, Fundamental & clinical pharmacology,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
December 1982, European journal of pharmacology,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
November 1984, The Journal of pharmacology and experimental therapeutics,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
November 1984, Acta pharmacologica et toxicologica,
J P Nunes, and D Moura, and S Guimarães, and I S de la Lande
January 1988, Life sciences,
Copied contents to your clipboard!